Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 11/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013910 | 1.00 | CCR5 (0.76) | CCR5KCNH2 | |
| SCHEMBL3073738 | 0.94 | CCR5 (0.69) | CCR5KCNH2 | |
| SCHEMBL3073740 | 0.94 | CCR5 (0.69) | CCR5KCNH2 | |
| SCHEMBL4016086 | 0.91 | CCR5 (0.90) | CCR5KCNH2 | |
| SCHEMBL4016090 | 0.91 | CCR5 (0.90) | CCR5KCNH2 | |
| SCHEMBL13718941 | 0.91 | CCR5 (0.67) | CCR5KCNH2 | |
| SCHEMBL3058167 | 0.89 | CCR5 (0.75) | CCR5KCNH2 | |
| SCHEMBL3058163 | 0.89 | CCR5 (0.75) | CCR5KCNH2 | |
| Ammonia Solution, Strong SCHEMBL3076184 | 0.88 | CCR5 (0.74) | CCR5KCNH2 | |
| Ammonia Solution, Strong SCHEMBL3076186 | 0.88 | CCR5 (0.74) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579471-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070185157-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-7217721-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1492789-B1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050107424-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6855724-B2 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | CCR5 1/4885KCNH2 2928/4885 |
| US-20050107424-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | CCR5 1/4885KCNH2 3530/4885 |
| US-20070185157-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | CCR5 1/4885KCNH2 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.